PCT Europe 2017, Amsterdam. In partnership with Synergy CRO, Cyntegrity presents the concept of #RealRBM: Hype or Common Sense. The main topics of the presentation are: The concept of integrity in Risk-based Monitoring Risks perception - differences in risk assessment between a sponsor and a CRO [...]
Interested in holistic implementation of the RBM? Let's talk in London by Clinical Operations Strategy Meeting (EU 2016) on Monday 11th July 2016. See the RBM session plan for the meeting: Interested in scheduling a meeting during the conference or after?[button link="https://cyntegrity.com/contact-info/" color="default" size="" stretch="" type="" shape="" [...]
We are pleased to announce that, on behalf of the DIA 2019 Annual Meeting Program Committee, our abstract titled: "Main Difference between Quality Tolerance Limits and Key Risk Indicators" has been accepted for a poster presentation at DIA 2019 in San Diego!
Our expert team reviewed the March 2019 RBM Q&A guidance document and extended the FDA guidance with RBM solution specific insights and a MindMap to help you even further.
Neat Features: wanting to dig a little deeper into the neat software features that make your risk-management life easy? Well, you’ve come to the right place. Learn more about Risk Flowers charts - a bunch of information.
Four RBQM case studies illustrate how our intelligent EarlyBird system forecasts future events and detects suspicious activity, to subsequently trigger on time preventive and corrective actions.
Our key risk indicator infographic will give you a foundational understanding of KRIs, provide valuable examples of KRIs, and guide you towards getting started with your risk-based monitoring (RBM) program.
Die Fachtagungen des DVMD sind jedes Mal ein informativer Querschnitt aus allen relevanten Themen rund um Dokumentation und Informationsmanagement in der Medizin. Jede Fachtagung greift dabei immer ein Schwerpunktthema auf. In 2019 wird es der Einfluss der Digitalisierung auf die Medizin sein.
Even without it being mandated, health authorities typically expect pharma and biotech companies to conduct two well-controlled Phase 3 trials demonstrating efficacy and safety. Still today this principle ensues discussions regarding the quantity and quality of the evidence needed to establish effectiveness.
DIA Europe is more than a traditional meeting. It's a chance to learn, engage, and grow as a healthcare professional alongside thousands of cross-functional collaborative leaders. Our CEO, Dr Artem Andrianov, will share his industry insights and expertise as one of the selected speakers. We hope your busy schedule will allow you to meet with Artem.